EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models

Xiaobo Zhang iD, Lixia Guan, Shuting Li, Shutong Chen, Miao-Miao Niu, Mengting Lou, Yang Zhou, Yunjiang Zhou, Weiwei Hu

Journal of Medicinal Chemistry · 14.05.2026 · 69 (9) · 10398-10412

DOI: 10.1021/acs.jmedchem.5c03539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 23.04.2026. Verfasst von Xiaobo Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 2…. Hauptthemen laut MEDLINE: Talin, Breast Neoplasms, Antineoplastic Agents, Peptides. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Changzhou Municipal Science and Technology Bureau, Double First Class University Plan, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TalinBreast NeoplasmsAntineoplastic AgentsPeptidesHumansFemaleAnimalsMiceCell ProliferationStructure-Activity RelationshipCell MovementMolecular Dynamics SimulationMDA-MB-231 CellsCell Line, TumorDrug DiscoveryProtein Binding

Substanzen

TalinAntineoplastic AgentsPeptides

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 211198, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Pathology, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou 213000, China.
  • Institute of Translational Medicine, China Pharmaceutical University, Nanjing 211198, China.

ORCID-Profile: Xiaobo Zhang

Förderung

  • Changzhou Municipal Science and Technology Bureau
  • Double First Class University Plan
  • National Natural Science Foundation of China
  • Outstanding Youth Program of the Lingang Laboratory
  • Basic Research Project of Changzhou Medical Center

Zitieren

APA

Zhang, X., Guan, L., Li, S., Chen, S., Niu, M. M., Lou, M., Zhou, Y., Zhou, Y., & Hu, W. (2026). Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models. Journal of Medicinal Chemistry, 69(9), 10398-10412. https://doi.org/10.1021/acs.jmedchem.5c03539

Vancouver

Zhang X, Guan L, Li S, Chen S, Niu MM, Lou M, et al. Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models. Journal of Medicinal Chemistry. 2026;69(9):10398-10412. doi:10.1021/acs.jmedchem.5c03539

BibTeX
@article{Zhang2026,
  author = {Zhang, Xiaobo and Guan, Lixia and Li, Shuting and Chen, Shutong and Niu, Miao-Miao and Lou, Mengting and Zhou, Yang and Zhou, Yunjiang and Hu, Weiwei},
  title = {Structure-Based Discovery of the First Inhibitor Targeting the Talin2-β-integrin Interaction with Potent In Vivo Antitumor Activity in Breast Cancer Models},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {9},
  pages = {10398--10412},
  doi = {10.1021/acs.jmedchem.5c03539}
}
Kostenlos starten →